Literature DB >> 34622346

Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics.

Jin Niu1, Van Anh Nguyen1, Mohammad Ghasemi1, Ting Chen1, Donald E Mager2.   

Abstract

Ordinary differential equation (ODE)-based models of signal transduction pathways often contain parameters that are unidentifiable or unmeasurable by experimental data, and calibrating such models to data remains challenging. Here, two efficient parameter estimation methods, cluster Gauss-Newton (CGN) and CellNOpt (CNO), were applied to fit a signaling network model of U266 multiple myeloma cells to the activity dynamics of key proteins in response to vorinostat and/or bortezomib. A logic-based network model was constructed and transformed to 17 ODEs with 79 parameters estimated within broad ranges of biologically plausible values. The top 10% best-fit parameters by both methods had high uncertainties with CV > 50% for the majority of parameters. The root mean square and prediction errors were comparable without statistically significant differences between the two methods. Despite uncertain parameter estimation, protein dynamics after the sequential combination of bortezomib and vorinostat was predicted with reasonable accuracy and precision. Global sensitivity analyses of partial rank correlation coefficients and Sobol sensitivity demonstrated that apoptosis induction was most sensitive to parameters governing the activity of the proteasome-JNK-caspase-8 axis. Simulations revealed that the greatest magnitude of pharmacodynamic drug interactions between bortezomib and vorinostat occurred at caspase-9, AKT, and Bcl-2. Two sequential combinations were explored in silico, and the outcome matched qualitatively with an empirical evaluation of the pharmacodynamic interaction based on cell viability. Overall, the CGN and CNO algorithms performed similarly for this ODE-based network model calibration, and the calibrated model provided meaningful insights into cellular signaling mechanisms in response to pharmacological perturbations.
© 2021. American Association of Pharmaceutical Scientists.

Entities:  

Keywords:  CellNOptR; Cluster Gauss–Newton method; Drug–drug interaction; Network modeling; Parameter estimation

Mesh:

Substances:

Year:  2021        PMID: 34622346      PMCID: PMC8653504          DOI: 10.1208/s12248-021-00640-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   3.603


  35 in total

1.  Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Authors:  Birgit Schoeberl; Emily A Pace; Jonathan B Fitzgerald; Brian D Harms; Lihui Xu; Lin Nie; Bryan Linggi; Ashish Kalra; Violette Paragas; Raghida Bukhalid; Viara Grantcharova; Neeraj Kohli; Kip A West; Magdalena Leszczyniecka; Michael J Feldhaus; Arthur J Kudla; Ulrik B Nielsen
Journal:  Sci Signal       Date:  2009-06-30       Impact factor: 8.192

Review 2.  Parameter estimation using meta-heuristics in systems biology: a comprehensive review.

Authors:  Jianyong Sun; Jonathan M Garibaldi; Charlie Hodgman
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2011-03-22       Impact factor: 3.710

3.  Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells.

Authors:  Charvi Nanavati; Donald E Mager
Journal:  Pharm Res       Date:  2017-01-18       Impact factor: 4.200

Review 4.  Pharmacodynamic Drug-Drug Interactions.

Authors:  Jin Niu; Robert M Straubinger; Donald E Mager
Journal:  Clin Pharmacol Ther       Date:  2019-04-26       Impact factor: 6.875

5.  Integrating literature-constrained and data-driven inference of signalling networks.

Authors:  Federica Eduati; Javier De Las Rivas; Barbara Di Camillo; Gianna Toffolo; Julio Saez-Rodriguez
Journal:  Bioinformatics       Date:  2012-06-25       Impact factor: 6.937

6.  Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model.

Authors:  Shun Asami; Daisuke Kiga; Akihiko Konagaya
Journal:  BMC Syst Biol       Date:  2017-12-21

7.  Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation.

Authors:  B Ribba; H P Grimm; B Agoram; M R Davies; K Gadkar; S Niederer; N van Riel; J Timmis; P H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-11

8.  Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma.

Authors:  Vidya Ramakrishnan; Donald E Mager
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-12-04

9.  Universally sloppy parameter sensitivities in systems biology models.

Authors:  Ryan N Gutenkunst; Joshua J Waterfall; Fergal P Casey; Kevin S Brown; Christopher R Myers; James P Sethna
Journal:  PLoS Comput Biol       Date:  2007-08-15       Impact factor: 4.475

10.  Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.

Authors:  G M Matthews; M Lefebure; M A Doyle; J Shortt; J Ellul; M Chesi; K M Banks; E Vidacs; D Faulkner; P Atadja; P L Bergsagel; R W Johnstone
Journal:  Cell Death Dis       Date:  2013-09-12       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.